Article

Good pseudoaccommodation with MICS lens at one year

The new MICS lens (Ioltech-Zeiss) is appropriate for the correction of intermediate vision in pseudophakia, according to Carlos Verges, Jorge Cazal and Marc Menezo of the Department of Ophthalmology, Institut Universitari Dexeus, Barcelona, Spain.

The new MICS lens (Ioltech-Zeiss) is appropriate for the correction of intermediate vision in pseudophakia, according to Carlos Verges, Jorge Cazal and Marc Menezo of the Department of Ophthalmology, Institut Universitari Dexeus, Barcelona, Spain.

The researchers presented the clinical results after one-year experience using the MICS lens. A total of 48 consecutive cataractous patients underwent MICS bimanual surgery and implantation of the lens using an incision of just 1.8 mm. The total diameter of the lens is just 12 mm allowing it to be positioned farther into the posterior plane than usual; 5.5 to 6 mm from the corneal endothelium at the nodal plane. The MTF, in the laboratory, was 92 changing to 80 with tilting conditions of 8º and decentration of 0.5 mm.

The results showed that, at one-year follow-up, 92% of subjects had an uncorrected distance visual acuity (UCDVA) of 20/25 and 96% a best corrected distance visual acuity (BCDVA) >20/25. 65% of patients achieved J3 with distance correction and 98% achieved J5. Two subjects required YAG laser for posterior capsule opacification (PCO) and two showed a folded haptic due to capsular retraction, not affecting vision or lens position. Three subjects reported glistening signs but vision was not affected.

Verges and his co-workers believe that the ability to position the lens at the level of the nodal planes combined with the lens' optical geometry allowing a pseudoaccommodative effect, makes the MICS lens appropriate for correct intermediate vision in pseudophakia.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Related Videos
Arun Gulani, MD: How the Gni instrument enhances precision and control in cataract surgery
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
© 2024 MJH Life Sciences

All rights reserved.